On Feb 5th, 2015 Equities researchers at JPMorgan Chase & Co. cut their price target on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from $53.00 to $47.00 in a research report issued on Friday. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price target indicates a potential upside of 36.11% from the stock’s previous close.
FBR Capital stated this last August. "We also believe Enanta could be an acquisition target, especially if 3D revenue exceeds expectations or if the early HCV pipeline advances."
Good sign that Gardiner Sr VP General Counsel is buying shares on the open market. Albeit it's only 2,800 shares but it is a purchase at $33.00+ and not an option conversion of cheap shares.
Given the current cash, payment for japan and future pipleine should't Abbott make a play for ENTA at this valuation? They won't have to pay any milestones for ABT493, get tights to ENTAs next gen NS5A and NASH drug candidate.
Cardica, Inc. (NASDAQ:CRDC): 2 Analyst have given the stock of Cardica, Inc. (NASDAQ:CRDC) a near short term price target of $1.38. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $0.53. The higher price target estimate is at $2 while the lower price estimates are fixed at $1.
Many Analysts from different Brokerage Firms have commented on the company rating and price targets.Craig-Hallum downgrades its rating on Cardica, Inc. (NASDAQ:CRDC). The global brokerage major lowers the current price target from $2.5 per share to $1 per share. Analysts at the Craig-Hallum have a current rating of Hold on the shares. The shares were previously rated Buy.
Cardica, Inc. (NASDAQ:CRDC), In a major negative the short interest in Cardica, Inc. shot up by 68.7% or 167,760 shares. The final shorts are 0.5% of the total floated shares. The positions increased from 244,110 shares on December 15,2014 to 411,870 on December 31,2014. Inculcating the per-day average trading of 440,784 shares, the days to cover are 1.
He's not the only capable engineer in the world! Nobody is bigger than the business. The have their patents and design. I'm sure the BOD is quite confident that can find a capable engineer to fix. Holding on to an employee that does not produce good results because you think there is nobody else out their that can do the job is a real sign of weak management.
I just saying people are now being held accountable. Can't have the wrong people in key seats. The new BOD smoked him account! That's progress. I'm sure they are making the necessary changes prior to the next earnings call update.
The BOD is doing exactly what it should, get the right people on the bus to move this thing forward. They have the courage to take action and I applaud them for getting it done. Hausen can focus all his efforts on R&D and bring in a CEO that can Lead! This is good news in my opinion and the first step to increasing share holder value.
My wild guess is that the CRDC update you are looking for will be given by a new CEO! The news and update will be more credible by a new leader with a track record. I think they are in the middle of a search and therefore the reason for the silence. I may be wrong, but having worked through similar situations at Medical Device companies this is my gut instinct on what's happening.
Vulcan, I can see why you are very negative. When you feel this way, it's best to move on. One can say with all the ugly or negative knowledge and no positive news at this point why the stock is holding steady here at $.67-.70 cents? On the other hand, one has to wonder why Broadfin has decided to use CRDC as it's first activist move? They have a great track record just look at FLML, ANGO and HZNP each of their top masterfund holdings that have all risen nicely since they acquired. Also, ISRG is in the final stages of their development on DaVinci. Why did they pick this platform for their Robot? And as I have stated before, having 3 FDA cleared devices with solid IP in a duopoly marketplace with expiring patents is very attractive. CRDC is going to get the expertise they need to maximize this new technology.
As the great Sir John Templeton said., "Buy at the point of maximum pessimism; sell at the point of maximum optimism". Templeton, a committed contrarian, believed the only way to get a bargain in the stock market was to buy when everyone else was selling: At the outbreak of World War II, when everyone else was panicking, he bought shares in every NYSE-listed company that was trading for less than $1--and made money on nearly all of them. He was early to see the benefits of diversifying outside of America; international investing became his signature style. It worked : $10,000 invested in his flagship fund in 1954 grew into $2 million by the time Templeton retired in 1992.
Jeremy, for the record Kevin is not a BOD member. None of the BOD members list their phone numbers. Bob Newell is listed as the PR Contact for Cardica. Others were listed only for the proxy vote. Have your read through the BOD bio's? Broadfin has definitely strengthened the BOD! Cardica needed some real accountability, sound decision-making and more credibility with the street. Broadfin has a great track record of of increasing value for shareholders. Just look at FLML, ANGO and HZNP. Their motives are aligned with us fellow shareholders.
Yes, in fact FLML made a top 5 pharma 2015 investment pick. Actually on Yahoo Finance home page along with Merck, BMS and LLY. Broadfin is the #1 shareholder. Also check out ANGO and HZNP. broadfin has a really good track record.
In this time of silence, I imagine their may some interviewing going on within the sr leadership team. I can see a new dynamic CEO and Hausen as the CTO. As disappointed as everyone is here, one must not forget that the IP of staple on a strip has real value. The stapling divisions of JNJ and MDT are their cash cows that much of their bundled contracts are driven. ISRG is a real believer in microcutter technology. This is the year you will see it on the DaVinci. Japan will approve microcutter. Also, the Medical Device Tax is very likely going to be repealed. Current stapler patents expire this year. Applied loses is JNJ bundled contract provision this year. It has been a real bumpy road, however, a best in class IP with FDA clearance is really worth a lot more than is currently being assigned. It's no easy business. If you've hung in this far, might as well hang in this year as we really are getting much closer to the finish line!
There is no benefit to releasing any news until the new year when all the tax sellers and traders are gone. When news is released the stock price can build a strong foundation. There were BOD meetings to discuss current status and game plan going forward. The form 4 options are the compensation for the new BODs first meeting. New BOD will get this thing on the right track. As far as Japan, there is no product to approve until it is available for sale. Microcutter currently is not on the market.
Bio agree with your comments here. Question is are ADC's only good for less toxicity and not increased efficacy? How did Kadcyla efficacy do so well in 2nd line trials? Will this bring into question all of IMGNs assets in terms of a leader in ADC platform? Have ADC's missed their window now with IDHN 1-2, PD-1 & CAR T? This is what I am looking forward in the full Marriane readout, Roche analysis and response for next steps.
Seattle Genetics: Good Tech, But On The Wrong Path
Dec. 18, 2014 6:42 PM ET | 9 comments | About: Seattle Genetics, Inc. (SGEN)
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
•ADC tech is superior.
•The management team are not good at commercialization.
•Fierce competition in lymphoma, bad strategy, timeline far away.
Credit Suisse Assigned $6 to Kadcyla Royalties, $7.00 Pipeline and $1 to NOL & Cash. This is an exaggerated affect due to options. It will settle in the $7-8 area after tax selling. This may actually make it more appealing to an acquirer such as Sanofi, Novartis or Amgen.